Streetbeat News

Stock Prices

BAK

Braskem shares are trading higher following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 2:47 pm

VKTX

Viking Therapeutics (NASDAQ:VKTX) has seen significant options trading activity, with a bullish sentiment prevailing among financial giants. Analysis of 18 unusual trades revealed 61% bullish and 38% bearish tendencies, with a notable interest in calls over puts. The trading range for VKTX is predicted between $5.0 and $90.0. Recent analyst ratings have varied, with an average target price of $95.0, though one analyst from Stifel downgraded the stock to Buy with a target price of $80. VKTX's current trading volume is 716,356, with a slight price decrease of -0.79%, now at $62.85. The stock's RSI indicates a neutral position, and its earnings release is anticipated in 36 days.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 2:46 pm

ORCL

Financial analysts have observed unusual options activity for Oracle (NYSE:ORCL), with a significant bullish sentiment. Analysis of 15 trades showed 66% bullish and 33% bearish tendencies, with a focus on a price band between $110.0 and $145.0. The largest trades included both calls and puts, with calls dominating in value and sentiment. Oracle's current market position shows a slight increase in stock price to $127.91, with potential overbought conditions indicated by the RSI. The next earnings report is expected in 83 days.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 2:46 pm

WULF

TeraWulf Inc. (NASDAQ:WULF) is anticipated to report a narrower Q4 loss of 2 cents per share compared to last year's 19 cents, with revenue expected at $24.16 million, up from $9.57 million. The company's preliminary FY23 revenue is projected at $69 million. Shares fell 2.8% to $1.73. Analysts from Cantor Fitzgerald, Stifel, Compass Point, and B. Riley Securities have provided ratings and price targets, with the most recent being an Overweight rating and a target of $4 from Cantor Fitzgerald.

Portfolio Pulse from Avi Kapoor

March 19, 2024 | 2:41 pm

NCMI

National CineMedia, Inc. (NASDAQ:NCMI) reported Q4 results surpassing expectations with $90.9 million in revenue and EPS of 24 cents, against consensus estimates of $81.1 million and 9 cents, respectively. The company anticipates Q1 2024 revenue between $34.5 million and $35.5 million, above the consensus of $32.47 million. A new $100 million share repurchase program was announced. Following the earnings beat, B. Riley Securities and Wedbush adjusted their price targets for NCMI to $6.75 (from $4.5) and $5.5 (from $4.5), respectively, with B. Riley upgrading the stock to Buy.

Portfolio Pulse from Avi Kapoor

March 19, 2024 | 2:41 pm

ABBNY

SWONF

SoftwareONE Holding AG announced that Timo Ihamuotila, CFO of ABB Ltd, and lawyer Isabelle Romy will leave its board at the next annual meeting. This move comes amid a power struggle with its founding shareholders. The board has rejected a proposal to replace it, except for Daniel von Stockar, but recommends electing a proportionate number of the 29%-block shareholders' nominees. ABB Ltd's shares fell 1.45% to $46.83.

Portfolio Pulse from Lekha Gupta

March 19, 2024 | 2:37 pm

APM

Aptorum Group Limited's shares resumed trading after a temporary halt due to a circuit breaker trigger. The halt was a response to significant trading activity or price movement.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 2:37 pm

ALPN

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) exceeded Q4 earnings expectations with a GAAP EPS of 15 cents against an expected loss of 29 cents and sales of $30.853 million versus the anticipated $9.104 million. The company highlighted significant progress in developing povetacicept for IgAN and other diseases, contributing to a 14.6% stock increase to $40.63. Analysts from HC Wainwright & Co., Oppenheimer, and Morgan Stanley subsequently raised their price targets for ALPN.

Portfolio Pulse from Avi Kapoor

March 19, 2024 | 2:35 pm

CNM

Core & Main's shares surged following the announcement of Q4 revenue results that exceeded expectations and the issuance of FY24 net sales guidance surpassing estimates.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 2:32 pm

CVNA

Carvana (NYSE:CVNA) has seen significant options trading activity, with a mix of bullish and bearish sentiments among investors. Analysis of 13 trades shows a nearly even split between bullish (46%) and bearish (53%) expectations. The trades include 7 puts and 6 calls, with a notable price target range from $69.0 to $125.0. The largest trades indicate a diverse sentiment, with both neutral and bearish positions on calls and puts. Carvana, an e-commerce platform for buying and selling used cars, is currently trading at $78.5, down 2.83%, with an RSI suggesting it may be approaching overbought territory. The company's earnings release is anticipated in 44 days.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 2:31 pm